



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

7th April 2017 - New research

P2B 001 (RASAGILINE AND PRAMIPEXOLE) FOR PARKINSON'S DISEASE

P2B 001 is a novel combination of (1) slow release and (2) low dose rasagiline and pramipexole for synergistic use in early Parkinson's Disease that is presently in development. For more information go to : http://www.pharma2b.com/en/45/FDC_for_parkinson.aspx Rasagiline is a MAO inhibitor for use in treating Parkinson's Disease. For more information go to : <http://www.rxlist.com/azilect-drug/patient-images-side-effects.htm> Pramipexole is a dopamine agonist that is also for use in Parkinson's Disease. For more information go to : <http://www.rxlist.com/mirapex-drug/patient-images-side-effects.htm>



People with early Parkinson's Disease were assessed when taking either : P2B 001 (0.3mg pramipexole / 0.75mg rasagiline), P2B001 (0.6mg pramipexole / 0.75mg rasagiline) or a placebo. The most effective of these was P2B 001 with a higher dose of pramipexole, followed by P2B 001 with a lower dose of pramipexole. Significant benefits were observed for both doses in : Parkinson Disease Quality of Life Scale-39 scores, the UPDRS (Parkinson's Disease) motor score, and activities of daily living. The adverse effects of P2B 001 were comparable to the use of a placebo apart from transient nausea and somnolence, which were more common with P2B 001 treatment.

Consequently, the researchers suggest that P2B 001 offers a promising treatment option for use in early Parkinson's Disease with good clinical efficacy and a low risk of adverse effects, in a way that can not be achieved by taking each of the drugs on their own.

Reference : Movement Disorders [2017] Apr 3 [Epub ahead of print] (C.W.Olanow, K. Kieburtz, M.Leinonen, L.Elmer, N.Giladi, R.A.Hauser, O.S.Klepiskaya, D.L.Kreitzman, M. F.Lew, D.S.Russell, S.Kadosh, P.Litman, H.Friedman, N.Linvah)

Complete abstract : <http://www.ncbi.nlm.nih.gov/pubmed/28370340>

<http://www.viartis.net/parkinsons.disease/news/170407.pdf>

mail@viartis.net

©2017 Viartis